NCT07479628 2026-03-18
Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
Shanghai Chest Hospital
Phase 2 Not yet recruiting
Clinical Trials
12 trialsNCT07132918 2026-03-11
HEARTS Trial for Thoracic Cancers
University of Wisconsin, Madison
Phase 2 Recruiting
NCT04417660 2026-02-05
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT07324629 2026-01-09
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Not yet recruiting
NCT03076554 2026-01-08
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01025089 2026-01-07
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06838910 2025-12-01
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03694002 2025-10-30
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT05104736 2025-09-19
PT-112 in Subjects With Thymoma and Thymic Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03463460 2025-08-24
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06186726 2025-06-13
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
Shanghai Proton and Heavy Ion Center
Phase 2 Recruiting